Castle Biosciences (CSTL) Total Debt (2018 - 2026)

Castle Biosciences has disclosed Total Debt across 7 years of filings, most recently posting $10.1 million for Q1 2026.

• Total Debt for Q1 2026 came in at $10.1 million, changed 0.34% year-over-year; the trailing twelve-month figure through Mar 2026 was $10.1 million (changed 0.34% YoY), and the FY2025 annual result was $10.1 million, changed 0.34% from the prior year.
• Total Debt came in at $10.1 million for Q1 2026 at Castle Biosciences, roughly flat from $10.1 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $20.8 million in Q1 2022 to a low of $10.0 million in Q1 2024.
• The 4-year median for Total Debt is $10.0 million (2025), against an average of $11.1 million.
• Peak annual rise in Total Debt reached 0.34% in 2025, while the deepest fall reached 0.32% in 2025.
• Castle Biosciences' Total Debt stood at $20.8 million in 2022, then slumped by 51.93% to $10.0 million in 2024, then gained by 0.34% to $10.1 million in 2025, then advanced by 0.09% to $10.1 million in 2026.
• The last three Total Debt figures came in at $10.1 million (Q1 2026), $10.1 million (Q4 2025), and $10.0 million (Q3 2025), per Business Quant data.